Myriad Genetics, Inc.

MYGN

$26.03

-2.6% last 12 months

Market Cap

$2.14 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$23.55 - $36.95

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

-28.5x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $2.14 Billion
Enterprise Value $1.77 Billion
Dividend Yield $0.00 (0.0%)
1 Year Return -2.6%
52-Week High $36.95
52-Week Low $23.55
Beta 1.55
Outstanding Shares 79.9 Million
Avg 30 Day Volume 530 Thousand

Valuation

P/E Ratio -28.5
PEG 10.89
Earnings per Share -$0.97
Price to Sales Ratio 3.25
Price to Book Ratio 2.17
Revenue to Enterprise Value 2.62
EBIT to Enterprise Value -9.6
Total Debt to Enterprise Value 0.0
Debt to Equity 0.0

Profitability

Revenue $675 Million
Gross Profit $479 Million
EBIT -$185 Million
Net Income -$34.8 Million
Profit Margin -5.16%
Quarterly Earnings Growth (YoY) -261.8%
Return on Equity -3.59%
Return on Assets -2.6%
Return on Invested Capital -16.3%

Insider trades

No purchases

89,543 shares sold (5 transactions)

No purchases

83,775 shares sold (6 transactions)

No purchases

1,420 shares sold (1 transactions)

No purchases

No sells

Q2 2021 Q3 2021 Q4 2021 Q1 2022

About Myriad Genetics, Inc.

CEO: R. Bryan Riggsbee

Employees: 2,600

Industry: Pharmaceutical Preparation Manufacturing

Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.

Similar stocks

Bio-Rad Laboratories Inc. - Class A
Bio-Rad Laboratories Inc. - Class A
Exact Sciences Corp.
Exact Sciences Corp.
Biocept Inc
Biocept Inc
Biomarin Pharmaceutical Inc. - Registered Shares
Biomarin Pharmaceutical Inc. - Registered Shares
Abbott Laboratories
Abbott Laboratories

News